Recro Pharma is a clinical stage specialty pharmaceutical company developing non-opioid therapeutics for the treatment of pain. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company's lead product candidate is an injectable form of meloxicam.

Type
Public
HQ
Malvern, US
Founded
2006
Size (employees)
195 (est)
Recro Pharma was founded in 2006 and is headquartered in Malvern, US
Report incorrect company information

Recro Pharma Office Locations

Recro Pharma has an office in Malvern
Malvern, US (HQ)
490 Lapp Rd
Show all (1)
Report incorrect company information

Recro Pharma Financials and Metrics

Recro Pharma Financials

Recro Pharma's revenue was reported to be $71.83 m in FY, 2017
USD

Revenue (FY, 2017)

71.8 m

Gross profit (FY, 2017)

33.6 m

Gross profit margin (FY, 2017), %

46.8%

Net income (FY, 2017)

(50.1 m)

EBIT (FY, 2017)

(40.3 m)

Market capitalization (18-Apr-2018)

218.4 m

Cash (31-Dec-2017)

61 m

EV

211 m
Recro Pharma's current market capitalization is $218.4 m.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Revenue

52 m69.3 m71.8 m

Revenue growth, %

33%

Cost of goods sold

28.1 m37.2 m38.2 m

Gross profit

23.9 m32.2 m33.6 m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Revenue

18.7 m16.5 m17.7 m17.3 m17 m18.7 m16.9 m

Cost of goods sold

9.4 m10 m10.3 m9.5 m5.7 m10.5 m10.4 m

Gross profit

9.3 m6.5 m7.5 m7.7 m11.2 m8.2 m6.5 m

Gross profit Margin, %

50%39%42%45%66%44%38%
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Cash

19.7 m19.8 m64.5 m61 m

Accounts Receivable

89.6 k8.6 m10.4 m9.7 m

Inventories

9 m1.1 m9.8 m

Current Assets

20.4 m38.7 m84.8 m87.3 m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Cash

29.9 m27.8 m23.9 m16.6 m15.7 m28.3 m14.9 m14.8 m24.8 m19.5 m8.7 m

Accounts Receivable

35.8 k86.8 k80.2 k15 m9.6 m12.2 m11.5 m12.4 m12.3 m10.1 m

Inventories

9.6 m8.6 m7.6 m6.7 m9.8 m7.8 m6.9 m

Current Assets

30.2 m28.1 m24.1 m17.3 m42.4 m48.4 m36.2 m35.2 m49 m77.3 m69.8 m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(16.1 m)3 m(30.2 m)(50.1 m)

Depreciation and Amortization

1.4 k4.1 m5 m4.9 m

Inventories

1.3 m(325 k)(1.1 m)

Accounts Payable

1.1 m2.2 m8.5 m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Net Income

(5.1 m)(7.9 m)(12.7 m)(4.1 m)(5.5 m)(7.6 m)(6.5 m)(14.4 m)(19.8 m)(8.1 m)(16.9 m)

Depreciation and Amortization

1.3 m2.7 m1.3 m2.5 m3.8 m1.2 m2.4 m

Inventories

345 k1.4 m1.3 m2.3 m(830 k)936 k1.9 m

Accounts Payable

306.9 k988.5 k1.6 m532.7 k4 m2.7 m2.6 m1.9 m4.5 m(2.4 m)
USDY, 2017

EV/EBIT

-5.2 x

Revenue/Employee

374.1 k

Financial Leverage

6.5 x
Show all financial metrics

Recro Pharma Operating Metrics

FY, 2016

Patents Issued

13
Show all operating metrics
Report incorrect company information